-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma partnership with Sobi for lacutamab in T-cell lymphomas takes effect, triggers USD 75 million upfront payment

PUBT·09/16/2026 20:00:38
Listen to the news
Innate Pharma partnership with Sobi for lacutamab in T-cell lymphomas takes effect, triggers USD 75 million upfront payment
  • Innate Pharma’s strategic partnership with Sobi for lacutamab in T-cell lymphomas took effect following completion of closing conditions.
  • Agreement triggers an upfront payment of USD 75 million.
  • Activation marks the start of the Phase 3 TELLOMAK-3 confirmatory trial in cutaneous T-cell lymphoma; first patient expected in Q1 2027.
  • Innate will run TELLOMAK-3; results intended to support full marketing applications for Sézary syndrome and mycosis fungoides.
  • Sobi holds exclusive global commercial rights after any accelerated approval; it can take full global development rights if Phase 3 is positive.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916527434) on September 16, 2026, and is solely responsible for the information contained therein.